AU2002349013A1 - Use of 7h-pyrrolo(2,3-d)pyrimidine derivatives in the treatment of solid tumor diseases - Google Patents

Use of 7h-pyrrolo(2,3-d)pyrimidine derivatives in the treatment of solid tumor diseases

Info

Publication number
AU2002349013A1
AU2002349013A1 AU2002349013A AU2002349013A AU2002349013A1 AU 2002349013 A1 AU2002349013 A1 AU 2002349013A1 AU 2002349013 A AU2002349013 A AU 2002349013A AU 2002349013 A AU2002349013 A AU 2002349013A AU 2002349013 A1 AU2002349013 A1 AU 2002349013A1
Authority
AU
Australia
Prior art keywords
pyrrolo
treatment
solid tumor
pyrimidine derivatives
tumor diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002349013A
Other languages
English (en)
Inventor
Howard Ashley Ball
Pamela Sarah Cohen
Lucy Lee
Christina Portrude Ravera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2002349013A1 publication Critical patent/AU2002349013A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2002349013A 2001-10-29 2002-10-28 Use of 7h-pyrrolo(2,3-d)pyrimidine derivatives in the treatment of solid tumor diseases Abandoned AU2002349013A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US34092301P 2001-10-29 2001-10-29
US60/340,923 2001-10-29
US36165502P 2002-03-05 2002-03-05
US60/361,655 2002-03-05
US37936502P 2002-05-09 2002-05-09
US60/379,365 2002-05-09
PCT/EP2002/012024 WO2003037897A2 (en) 2001-10-29 2002-10-28 Use of 7h-pyrrolo[2,3-d]pyrimidine derivatives in the treatment of solid tumor diseases

Publications (1)

Publication Number Publication Date
AU2002349013A1 true AU2002349013A1 (en) 2003-05-12

Family

ID=27407431

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002349013A Abandoned AU2002349013A1 (en) 2001-10-29 2002-10-28 Use of 7h-pyrrolo(2,3-d)pyrimidine derivatives in the treatment of solid tumor diseases

Country Status (5)

Country Link
US (1) US20050038048A1 (enExample)
EP (1) EP1441736A2 (enExample)
JP (1) JP2005507424A (enExample)
AU (1) AU2002349013A1 (enExample)
WO (1) WO2003037897A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005039588A2 (en) * 2003-10-22 2005-05-06 Novartis Ag Methods for determining the risk of developing liver and lung toxicity
AR047470A1 (es) * 2004-01-29 2006-01-18 Novartis Ag Derivados de pirrolo-pirimidina utiles para el tratamiento de enfermedades proliferativas,composiciones farmaceuticas que los contienen,y procesos para su preparacion
GB0403606D0 (en) * 2004-02-18 2004-03-24 Novartis Ag Organic compounds
JP5345323B2 (ja) 2004-12-15 2013-11-20 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ 癌を処置するための治療剤の組合せ
EP1909788A2 (en) 2005-07-29 2008-04-16 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
WO2007082946A1 (en) * 2006-01-23 2007-07-26 Novartis Ag Solid forms of a pyrrolopyrimidine derivative and their use as anti-tumor agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4146514B2 (ja) * 1995-07-06 2008-09-10 ノバルティス アクチエンゲゼルシャフト ピロロピリミジン類およびその製造方法
ES2177925T3 (es) * 1996-01-23 2002-12-16 Novartis Ag Pirrolopirimidinas y procedimientos para su preparacion.
GB9925958D0 (en) * 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
CA2427622A1 (en) * 2000-11-03 2002-05-16 Isaiah J. Fidler Methods for detecting the efficacy of anticancer treatments
ES2290199T3 (es) * 2000-11-22 2008-02-16 Novartis Ag Mezcla que incluye un agente que reduce la actividad de fcve y un agente que reduce la actividad de fce.
AU2002308218B2 (en) * 2001-02-27 2005-11-10 Novartis Ag Combination comprising a signal transduction inhibitor and an epothilone derivative

Also Published As

Publication number Publication date
US20050038048A1 (en) 2005-02-17
JP2005507424A (ja) 2005-03-17
WO2003037897A3 (en) 2003-09-18
WO2003037897A2 (en) 2003-05-08
EP1441736A2 (en) 2004-08-04

Similar Documents

Publication Publication Date Title
PL377239A1 (pl) Nowe amino-podstawione pochodne dihydropirymido [4,5-d]-pirymidynonu, ich wytwarzanie i zastosowanie jako środków framaceutycznych
AU2001291893A1 (en) Use of substituted imidazo(1,2-a)pyridine-, imidazo(1,2-a)pyrimidine and imidazo(1,2-a)pyrazine-3-yl-amine derivatives for producing NOS-inhibiting medicaments
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
AP2002002456A0 (en) Pyrazolo '4,3-d pyrimidine derivatives
AU2002340999A1 (en) Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
ZA200306886B (en) Pyrazolopyrimidines as therapeutic agents.
PL377227A1 (pl) Postawione pochodne heksahydropirazyno [1,2-a] pirymidyno-4,7-dionu, sposób ich wytwarzania i ich zastosowanie jako środków leczniczych
IL160397A0 (en) Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido{1,2-a} pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo {1,2-a} pyrimidin-5 (1h) one derivatives for neurodegenerative disorders
IL160402A0 (en) Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido {1,2-a} pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo{1,2-pyrimidin-5 (1h) one derivatives
PL1603915T3 (pl) Podstawione pochodne 8-pirydynylo-dihydrospiro-cykloalkilo-pirymido-1,2-a-pirymidyn-6-onu i 8-pirymidynylo-dihydrospiro-cykloalkilo-pirymido-1,2-a-pirymidyn-6-onu oraz ich zastosowanie przeciwko chorobom neurodegeneracyjnym
AU2001260834A1 (en) The treatment of herpes
AP2329A (en) 2-Substituted phenyl-5, 7-dihydrocarbyl-3, 7-dihydropyrrolo [2,3-d] pyrimidin-4 - one derivatives, the preparation and the pharmaceutical use thereof.
TWI320413B (en) 1,4-diazabicyclo [ 3.2.2 ] nonanecarboxamide derivatives, preparation thereof and therapeutic use thereof
AU2002349013A1 (en) Use of 7h-pyrrolo(2,3-d)pyrimidine derivatives in the treatment of solid tumor diseases
AU2002215979A1 (en) Use of pyrazolo(4,3-D)pyrimidines
AU2002352566A1 (en) Use of corrinoids in the treatment of skin diseases
MXPA03008894A (es) Uso de compuestos de imidazo[1,2-a]-piridin-3-il-amidas e imidazo [1,2-a]-piridin-3-il-aminas sustituidas como medicamentos.
AU2002216033A1 (en) Use of pyrazolo(4,3-d)pyrimidines
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
AU2002350513A1 (en) Use of solasonine for the treatment of skin tumors
AU2002306413A1 (en) Use of pyrido`2,3-d pyrimidin derivatives for the treatment of human cytomegalovirus infections
AU2002357468A1 (en) Use of 2-acylindoles in the treatment of tumors
AUPQ475499A0 (en) Phosphoglycerate kinase in the treatment of disease
AU2002365654A1 (en) Treatment of diseases via the skin
AU2002223961A1 (en) Use of chelators in the treatment of macular degenerative disease

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase